Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Gland Pharma's Enterprise Value is ₹451,674 Mil.
Gland Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil. Therefore, Gland Pharma's EV-to-OCF for today is .
The historical rank and industry rank for Gland Pharma's EV-to-OCF or its related term are showing as below:
NSE:GLAND'
s EV-to-OCF Range Over the Past 10 Years
Min: 38.62 Med: 110.21 Max: 895.67
Current: 38.62
During the past 9 years, the highest EV-to-OCF of Gland Pharma was 895.67. The lowest was 38.62. And the median was 110.21.
NSE:GLAND's EV-to-OCF is ranked worse than 83.6% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.055
vs NSE:GLAND: 38.62
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gland Pharma's PE Ratio (TTM) for today is calculated as:
Gland Pharma's share price for today is ₹2924.40.
Gland Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹68.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gland Pharma EV-to-OCF Related Terms
Gland Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Gland Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Gland Pharma's EV-to-OCF falls into.
Gland Pharma's current Enterprise Value is ₹451,674 Mil.
Gland Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,924.40 is trading 30% above its estimated GF Value™ of ₹2,249.62.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
EV-to-OCF:
GF Value™: ₹2,249.62 vs. price of ₹2,924.40 (30% above fair value)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
81GF Score
Get the complete analysis for NSE:GLAND
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
